Ibrutinib in early stage CLL: Genetic risk factors and treatment outcome in the GCLLSG CLL12 trial - PubMed
6 hours ago
- #Chronic Lymphocytic Leukemia
- #Ibrutinib
- #Genetic Risk Factors
- Ibrutinib improves event-free survival (EFS) in early-stage CLL with intermediate to very high risk, but shows no overall survival (OS) benefit.
- Genetic factors like del(17p), TP53 mutations, U-IGHV, and others predict poorer EFS in the placebo group, while only del(17p), TP53, and NFKBIE mutations affect EFS with ibrutinib.
- Ibrutinib benefits EFS in subgroups with U-IGHV, del(11q), +12, NOTCH1, ATM, and NFKBIE mutations, but not in those with del(17p) or TP53 mutations.
- Multivariable analysis identifies ibrutinib as a favorable factor for EFS, with U-IGHV, del(17p), POT1, RAS/RAF, and NFKBIE mutations as adverse prognostic factors.
- Watch-and-wait remains standard care for early-stage CLL, particularly in high-risk cases involving del(17p) or TP53 mutations.